



1614  
JFW


Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/591,315	
	Filing Date	September 1, 2006	
	First Named Inventor	Kai Wucherpennig	
	Art Unit	1614	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	10	Attorney Docket Number	PEPT-P01-006

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Reply to Missing Parts/Incomplete Application  <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____  <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input type="checkbox"/> Other Enclosure(s) (please identify below):  SB/08 Copy of references BA-BN and CA-CRR Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	FISH & NEAVE IP GROUP, ROPES & GRAY LLP		
Signature			
Printed name	Erika Takeuchi		
Date	May 9, 2007	Reg. No.	55,661

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: May 9, 2007	Signature:  (Linda Blake)



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to:  
MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: May 9, 2007

Signature: Linda Blake

(Linda Blake)

Docket No.: PEPT-P01-006  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Wucherpennig et al.

Application No.: 10/591,315

Confirmation No.: 9509

Filed: September 1, 2006

Art Unit: 1614

For: **METHODS AND COMPOSITIONS FOR  
TREATMENT OF AUTOIMMUNE  
DISEASES**

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. PEPT-P01-006. A duplicate copy of this paper is enclosed.

Dated: May 9, 2007

Respectfully submitted,

By   
Erika Takeuchi

Registration No.: 55,661  
FISH & NEAVE IP GROUP,  
ROPES & GRAY LLP  
1211 Avenue of the Americas  
New York, New York 10036-8704  
(212) 596-9000  
(212) 596-9090 (Fax)  
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/591,315
				Filing Date	September 1, 2006
				First Named Inventor	Kai W. Wucherpennig
				Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	1	of	4	Attorney Docket Number	PEPT-P01-006

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (# known)			
	AA	US-6,844,314	01-18-2005	Eisenbach-Schwartz et al.	
	AB	US-2004/0038887	02-26-2004	Strominger et al.	
	AC	US-2002/0183385	12-05-2002	Ellison et al.	
	AD	US-2002/0055455	05-09-2002	Aharoni et al.	
	AE	US 2003/0004099	01-02-2003	Eisenbach-Schwartz et al.	
	AF	US-6,214,791	04-10-2001	Arnon et al.	
	AG	US-5,858,964	01-12-1999	Aharoni et al.	
	AH	US-5,800,808	09-01-1998	Konfino et al.	
	AI	US-3,849,550	11-19-1974	Teitelbaum et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO 06/031727	03-23-2006	Harvard College U.S.		
	BB	WO 05/032482	04-14-2005	Bayhill Therapeutics Inc.		
	BC	WO 05/112972	12-01-2005	Peptimmune Inc.		
	BD	WO 05/120542	12-22-2005	Peptimmune Inc.		
	BE	WO 04/064717	08-05-2004	Yeda Research and Development Co. Ltd.		
	BF	WO 03/000277	01-03-2003	The Hospital for Sick Children		
	BG	WO 03/029276	04-10-2003	President and Fellows of Harvard College		
	BH	WO 01/18794	04-06-2000	Yeda Research and Development Co.,		
	BI	WO 00/20010	04-13-2000	Teva Pharmaceuticals USA, Inc.		
	BJ	WO 00/05250	02-03-2000	Yeda Research and Development Co. Ltd.		
	BK	WO 00/05249	02-03-2000	The President and Fellows of Harvard College		
	BL	WO 92/02543	02-20-1992	Cytel Corporation		
	BM	WO 00/27417	05-18-2000	Yeda Research and Development Co., Ltd.		
	BN	WO 03/047500	06-12-2003	Yeda Research and Development Co., Ltd.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/591,315
				Filing Date	September 1, 2006
				First Named Inventor	Kai W. Wucherpfennig
				Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	2	of	4	Attorney Docket Number	PEPT-P01-006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	ALTMANN, D., "Evaluating the Evidence for Multiple Sclerosis as an Autoimmune Disease", ARCH Neurol., Vol. 62, pp. 688-690, 2005.	
	CB	BARNETT, M., et al., "Relapsing and Remitting Multiple Sclerosis: Pathology of the Newly Forming Lesion", Ann. Neurol., 55: 458-468, 2004.	
	CC	BOGGIANO, C., et al., "Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV-1 CTL epitope Gag 77-85", Eur. J. Immunol., 35:1428-1437 (2005).	
	CD	BOURDETTE, D. et al., "Immunity to TCR Peptides in Multiple Sclerosis", J Immunol., 152: 2510-2519 (1994).	
	CE	CHAUDHURI, A., et al., "Multiple Sclerosis Is Not an Autoimmune Disease", Arch. Neurol., Vol. 61, pp. 1610-1612, 2004.	
	CF	DHIB-JALBUT, S., "Glatiramer acetate (cCpaxone) therapy for multiple sclerosis", Pharmacology & Therapeutics, 98 (2003), pp. 245-255.	
	CG	FAIRCHILD, P. et al., "Altered peptide ligands as therapeutic agents for the treatment of allograft rejection", Current Topics in Peptide & Protein Research, Vol. 6, 237-244 (2004).	
	CH	FARINA et al., "Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action", The Lancet (Neurology), Vol. 4, 567-575, September 2005.	
	CI	FLECHTER et al., "Copolymer 1 (Glatiramer Acetate) in Relapsing Forms of Multiple Sclerosis: Open Multicenter Study of Alternae-Day Administration", Clinical Neuropharmacology, Vol. 25, No. 1, 11-15, 2002.	
	CJ	FRANK, R., "Principles of simultaneous synthesis of multiple peptides", Screening of T and B cell epitopes, Chapter 10.3, 778-781, (1997).	
	CK	FRIDKIS-HARELI, M., et al., "Binding Motifs of Copolymer 1 to Multiple Sclerosis- and Rheumatoid Arthritis-Associated HLA-DR Molecules, J of Immunol, 162: 4697-4704 (1998).	
	CL	FRIDKIS-HARELI et al., "Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity", Proc. Natl. Acad. Sci. USA, Vol. 91, 4872-4876, May 1994.	
	CM	FRIDKIS-HARELI et al., "Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis", The J Clin Invest, Vol. 109, No. 12, 1635-1643, June 2002.	
	CN	HANCOCK, W. et al., "Differential Effects of Oral Versus Intrathymic Administration of Polymorphic Major Histocompatibility Complex Class II Peptides on Mononuclear and Endothelial Cell Activation and Cytokine Expression during a Delayed-Type Hypersensitivity Response", Amer J Pathol, Vol. 144, No. 6, 1149-1158, (1994).	
	CO	HOUGHTEN, R., et al., "Mixture-Based Synthetic Combinatorial Libraries", Journal of Medical Chemistry, Vol. 42, No. 19, 3643-3778, 1999.	
	CP	<a href="http://eanatomy.cc/4.htm">http://eanatomy.cc/4.htm</a> , Section 4, The Acquired Immune Respose, 1-71, May 9, 2005.	
	CQ	ILLES ZSOLT et al., "Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells", Proc. Natl. Acad. Sci; Vol. 101, No. 32, (2004) (Abstract)	
	CR	JACCHIERI et al., "Proving the Influence of Sequence-Dependent Interactions upon $\alpha$ -Helix Stability in Alanine-Based Linear Peptides", Biopolymers, Vol. 33, No. 6, 971-984, 1993.	
	CS	KARANDIKAR et al., "Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis", J Clin Invest, Vol. 109, No. 5, 641-649, March 2002.	
	CT	KERSTEN et al., "Antigen delivery systems", Expert Rev. Vaccines 3(4), 453-462, 2004.	
Examiner Signature			Date Considered



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/591,315		
		Filing Date	September 1, 2006		
		First Named Inventor	Kai W. Wucherpfennig		
		Art Unit	1614		
		Examiner Name	Not yet assigned		
Sheet	3	of	4	Attorney Docket Number	PEPT-P01-006

CU	KMLE Medical Dictionary – Online medical dictionary, terminology, abbreviations, drugs, pp. 1-8, 2006-2007.	
CV	LA ROSA, C., "Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries", Blood, Vol. 97, No. 6, 1776-1786, (2001).	
CW	LAURSEN, R., et al., "Case Study 4-5 Characterization of the Epitope Specificity of Antibodies Using Membrane-Bound Peptides", supplied by the British Library, 117-122.	
CX	LAWENDOWSKI, C., et al., "Solid-Phase Epitope Recovery: A High Throughput Method for Antigen Identification and Epitope Optimization", J of Immunol, 169: 2414-2421, (2002).	
CY	LEBL, M., et al., "High-Throughput Peptide Synthesis", Methods in Molecular Biology, Vol. 298, Peptide Synthesis and Applications, 167-194 (2005).	
CZ	LUSTGARTEN, J., et al., "Identification of Cross-Reactive Peptides Using Combinatorial Libraries Circumvents Tolerance against Her-2/neu-Immunodominant Epitope", J of Immunol, 176: 1796-1805 (2005).	
CAA	MAGEE, C., et al., "Novel Strategies Using MHC Peptides", Therapeutic Immunosuppression, 101-126 (2001).	
CBB	Merriam Webster's Collegiate Dictionary, Tenth Edition, 1996, pg. 36	
CCC	NIEDERHAFNER, P., et al., "Peptide dendrimers", J of Peptide Sci, 11, 757-788 (2005).	
CDD	PAPASSAVAS, A., "HLA Peptide-mediated Strategies for Modulation of Cellular and Humoral Immune Response in Transplantation", Curr Pharmacogenomics, Vol. 1, No. 1, 17-36 (2003).	
CEE	PINILLA, C., et al., "Exploring immunological specificity using synthetic peptide combinatorial libraries", Curr Op Immunol, 11:193-202 (1999).	
CFF	PINILLA, C., et al., "Investigation of antigen-antibody interactions using a soluble, non-support-bound synthetic decapeptide library composed of four trillion (4 x 10 <sup>12</sup> ) sequences, Biochem. J. 301, 847-853 (1994).	
CGG	PRAKKEN, B., et al., "Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis", PNAS, Vol. 101, No. 12, 4228-4233 (2004).	
CHH	QUANDT, J., et al., "Peptidic complex mixtures as therapeutic agents in CNS autoimmunity", Mole Immunol 40, 1075-1087 (2004).	
CII	REINEKE, U., "Antibody Epitope Mapping Using Arrays of Synthetic Peptides", Methods in Mole Biol, Vol. 248443-463 (2004).	
CJJ	SADLER, K., et al., "Peptide dendrimers: applications and synthesis" Reviews in Molecular Biotechnol 90, 195-229 (2002).	
CKK	SAYEGH, M., et al., "Mechanisms of Acquired Thymic Unresponsiveness to Renal Allografts", Transplantation, Vol. 58, No. 2, 125-132, (1994).	
CLL	SAYEGH, M., et al., "Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat", Proc. Natl. Acad. Sci. USA, Vol. 89, 7762-7766 (1992).	
CMM	SELIGMANN, B., et al., "Solid-Phase Peptide Synthesis, Lead Generation, and Optimization", Combinatorial Chemistry and Molecular Diversity in Drug Discovery, 39-109, 1998.	
CNN	SHIN, D., et al., "Combinatorial Solid Phase Peptide Synthesis and Bioassays", J Biochem and Mole Biol, Vol. 38, No. 5, 517-525, (2005).	
COO	T'HART, B., et al., "Evaluating the validity of animal models for research into therapies for immune-based disorders", Drug Discovery Today, Vol. 9, No. 12, pp. 517-524, 2004.	
CPP	TSOKOS, G., "B Cells, Be Gone – B –Cell Depletion in the Treatment of Rheumatoid Arthritis, N. Engl J. Med 350, (25), pp. 2546-2548, 2004.	
CQQ	WALDMANN, H., "Development and Clinical Use of CAMPATH 1H", Transplantation Rev., Vol. 17, No. 4, pp. S5-S7, 2003.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/591,315
				Filing Date	September 1, 2006
				First Named Inventor	Kai W. Wucherpfennig
				Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	4	of	4	Attorney Docket Number	PEPT-P01-006

	CRR	WANG, B., et al., "Multiple Paths for Activation of Naive CD8+ T Cells: CS4-Independent Help", J of Immunol, 167: 1283-1289 (2001).	
--	-----	---	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Application No. (if known): 10/591,315

Attorney Docket No.: PEPT-P01-006

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on May 9, 2007  
Date

Linda Blake

Signature

Linda Blake

Typed or printed name of person signing Certificate

Registration Number, if applicable

(212) 596-9000  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)  
Information Disclosure Statement (2 pages, in duplicate; total: 4 pages)  
SB/08 (4 pages, 67 references)  
Copy of references BA-BN and CA-CRR  
Return receipt postcard  
This Certificate of Mailing under 37 CFR 1.8